RE:RE:Time for growth "cowards won't give forward guidance. Instead, use weasel words in MD&A:
"Ceapro’s quarterly sales and results primarily fluctuate due to variations in the timing of customer orders, different product mixes, and changes in the capacity to manufacture products.""
Those aren't weasel words. Those are facts.
Gilles is relying on facts by presenting the actual quarterly number with financials. You want forward guidance or speculative BS based on a number of factors.
Since neither you nor Gilles is provided specific insight into Symrise's clients individual demand why haven't you been providing speculative BS forward guidance to make a fool of yourself? I guess you are the coward by your own standard. Given you've bashed CZO all the way up your forward guidance in tone sure has made you the fool.
Given the quarter to quarter volitility it is best to stick to trailing 12 month revenue which also accounts for seasonality as CZO's first two quarters have tended to be the strongest. Given the pipeline is now before key catalysts the importance of the base business is also becoming less significant to overall value at the current share price.